Magenta

Mount Sinai South Nassau

Mount Sinai Beth Israel

Mount Sinai Morningside

Mount Sinai Brooklyn

Mount Sinai Queens

The Mount Sinai Hospital

New York Eye and Ear Infirmary of Mount Sinai

Mount Sinai West

Bronchoscopy, Diagnostic

COVID-19 Lung Disease

Lung Cancer

Lung Mass

Consulting or Other Professional Services

Equity

FOLLOW UP

Book with a provider you have not seen before

NEW PATIENT

Book a virtual visit with a provider you have seen before

VIDEO VISIT - FOLLOW UP

Book a virtual visit with a provider you have not seen before

VIDEO VISIT - NEW PATIENT

Pulmonary and Critical Care Medicine

DIRECTOR, MOUNT SINAI-NATIONAL JEWISH HEALTH RESPIRATORY INSTITUTE

Pulmonary, Critical Care and Sleep Medicine

Medicine

PROFESSOR

Lung adenocarcinoma can progress from an indolent in situ carcinoma to an invasive, aggressive, metastatic tumor. The WHO/IASLC/ATS Lung adenocarcinoma classification emphasizes the distinction of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma from their invasive counterparts.&nbsp; Molecular biomarkers of invasion can distinguish invasive from non-invasive tumors, a distinction that is typically difficult to make in small biopsies and cytology specimens and is becoming increasingly important as the recognition of early stage adenocarcinoma increases with the widespread implementation of lung cancer screening programs in the United States. Please visit the <a href="http://labs.icahn.mssm.edu/powell-lab/">Charles Powell Lab</a>.

Internal Medicine

Pulmonary Medicine (Lung)

Sleep Medicine

Charles Powell, MD, is a Professor Medicine and Chief of the Division of Pulmonary, Critical Care and Sleep Medicine. He is also the CEO of the Mount Sinai-National Jewish Health Respiratory Institute.

He is Chair of the Thoracic Oncology Section of the American Thoracic Society, an elected member of the Fleischner Society, and a recipient of the American

Charles Powell, MD

Schedule An Appointment

Charles A Powell, MD, MBA